Respiratory Infections

Ceftolozane and tazobactam proves noninferior to meropenem in a pivotal phase 3 trial of adult patients with HABP or VABP.

Mindy Smith, BSPharm, RPh, shares common misconceptions about the flu shot and how providers can advocate for the vaccination to their patients.

Public Health England recommends individuals at higher risks for influenza receive a newly available adjuvanted trivalent influenza vaccine this winter.

Investigators from the NIH have launched a phase 1 clinical trial to assess if a topical cream administered prior to H5N1 vaccination can enhance immune response.

An international literature review indicates that 78% of children with multidrug-resistant tuberculosis were successfully treated with second-line treatment.

A team of investigators have discovered a new way to link samples submitted for TB testing to individuals who provided them as well as where the sample was collected.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

A Legionnaires’ disease outbreak in New Hampshire has been linked to at least 1 resort in the town of Hampton.

Troy Trygstad, PharmD, MBA, PhD, discusses the trends of targeted research in the influenza vaccination space and how protocols could differ based off of variances.

New research finds that the flu vaccine is more successful in women than in men, but the complexity of the issue makes it difficult to know exactly why that is.

Investigators find telavancin has potent in vitro activity and low resistance development potential when used against S aureus isolates in patients with cystic fibrosis.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Investigators from Loyola Medicine have developed a 3-pronged model that could identify patients at risk for acute respiratory distress syndrome.

A new study by St. Jude Children’s Research Hospital reported that gamma delta (γδ) T cells play a key role in protecting infants from flu complications.

A universal flu vaccine candidate elicits protective response in mice against multiple strains of the virus.

A sputum molecular testing algorithm accurately identified TB and was easily implemented in a center in San Francisco.

In a wounded mouse model concurrently infected with influenza A, investigators observed that the innate immune system prioritized responding to the lung infection, delaying wound healing.

New recommendations from the CDC's Advisory Committee on Immunization Practices reveal that health care providers have the intranasally-administered live attenuated influenza vaccine (LAIV) among their arsenal of available vaccines for the 2018-2019 flu season.

Health care providers, especially those practicing in the southern United States, should consider angiostrongyliasis in patients with eosinophilic meningitis.

The incidence of Neisseria meningitidis serogroup W is rising in Georgia.

Julie Ann Justo, PharmD, MS, BCPS-AQ ID, provides an example of how institution-specific information can be used to generate a customized risk score.

The PDUFA action date has been set for February 13, 2019.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

The FDA advisory committee voted 17 to 1 in favor of omadacycline for treatment of ABSSSI and 14 to 4 for the treatment of CABP.

If approved, ALIS will be the first and only therapy available in the United States that will be specifically indicated for the treatment of patients with NTM lung disease caused by MAC.

Investigators report that the duration of viral shedding of influenza A in obese adults was 42% longer than nonobese adults.

New research suggests 4 months of rifampin produced higher rates of adherence than 9 months of isoniazid in individuals with latent tuberculosis.

With vaccine efficacy during the 2017–2018 flu season under question, a novel antiviral agent may provide a solution.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Gram-negative organisms are showing up at higher rates in seriously ill pneumonia patients. What are the best antibiotics to prescribe, given the real risk of death and the need to avoid contributing to drug resistance?